IP Library Granted Patent US 10,251,851
Granted Patent B2
US 10,251,851 · App. 15/633,480 · Granted Apr 9, 2019

Bicyclic analgesic compounds

Inventor: Kevin Duane Bunker (San Diego, CA)
Assignee: Zeno Royalties & Milestones, LLC
A61K31/16A61K9/0014A61K9/0019A61K31/13A61K31/133A61K31/14A61K31/215A61K31/216A61K31/22A61K31/221A61K31/235A61K31/24A61K45/06C07C211/62C07C217/52C07C233/06C07C233/23C07C233/41C07C233/52C07C233/63C07C235/74C07C2602/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,251,851
App. No.
15/633,480
Granted
Apr 9, 2019
Kind
B2
Abstract

Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.

Claims (43)

1. A method for reducing pain or fever comprising administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:

wherein

R 1 is H or —CH 3 ;

R 2 is H or —C(═Y)R 4 ;

R 3 is H, hydroxy, NH 2 , an unsubstituted (C 1 to C 10 ) alkoxy, an unsubstituted (C 1 to C 6 )alkyl, an unsubstituted mono-cyclic (C 3 to C 6 ) cycloalkyl, an unsubstituted —NC(═O)—C 1-6 alkyl, (C═O)OR 6 or O(C═O)R 5 ;

R 4 is an unsubstituted (C 1 to C 10 ) alkyl or CF 3 ;

R 5 is an unsubstituted (C 1 to C 6 ) alkyl, a substituted or unsubstituted benzyl or

R 6 is an unsubstituted (C 1 to C 30 ) alkyl; and

Y is O.

2. The method of claim 1 , further comprising administering an opioid analgesic.

3. The method of claim 2 , wherein the opioid analgesic is selected from the group consisting of morphine, codeine, hydrocodone, oxycodone, fentanyl, pethidine, methadone, pentazocine, sufentanil, levorphanol, dihydrocodeine, nalbuphine, butorphanol, tramadol, meptazinol, buprenorphine, dipipanone, alfentanil, remifentanil, oxymorphone, tapentadol, propoxyphene and hydromorphone.

4. The method of claim 1 , wherein the administration is intravenous or topical.

5. The method of claim 1 , wherein the pain is post-operative pain.

6. The method of claim 1 , wherein R 2 is —C(═Y)R 4 ; and R 1 is H.

7. The method of claim 1 , wherein R 2 is H; and R 1 is H.

8. The method of claim 1 , wherein R 3 is H.

9. The method of claim 1 , wherein R 3 is hydroxy or an unsubstituted (C 1 to C 10 ) alkoxy.

10. The method of claim 1 , wherein R 3 is an unsubstituted (C 1 to C 6 )alkyl.

11. The method of claim 1 , wherein R 3 is an unsubstituted mono-cyclic (C 3 to C 6 ) cycloalkyl.

12. The method of claim 1 , wherein R 3 is NH 2 or an unsubstituted —NC(═O)—C 1-6 alkyl.

13. The method of claim 1 , wherein R 3 is —(C═O)OR 6 , wherein R 6 is an unsubstituted (C 1 to C 30 ) alkyl; or —O(C═O)R 5 , wherein R 5 is an unsubstituted (C 1 to C 6 ) alkyl, a substituted or unsubstituted benzyl or

14. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

wherein

R 1 is H or —CH 3 ;

R 2 is —C(═Y)R 4 ; and

R 3 is H, hydroxy, NH 2 , an unsubstituted (C 1 to C 10 ) alkoxy, an unsubstituted (C 1 to C 6 )alkyl, an unsubstituted mono-cyclic (C 3 to C 6 ) cycloalkyl, an unsubstituted —NC(═O)—C 1-6 alkyl, —(C═O)OR 6 or —O(C═O)R 5 ; or

R 1 is H;

R 2 is H;

R 3 is an unsubstituted (C 1 to C 10 ) alkoxy or an unsubstituted (C 2 to C 6 ) alkyl;

R 4 is an unsubstituted (C 1 to C 10 ) alkyl or CF 3 ;

R 5 is a substituted benzyl or

R 6 is an unsubstituted (C 1 to C 30 ) alkyl; and

Y is O.

15. The compound of claim 14 , wherein R 2 is —C(═Y)R 4 ; and R 1 is H.

16. The compound of claim 14 , wherein R 2 is H; and R 1 is H.

17. The compound of claim 14 , wherein R 3 is H.

18. The compound of claim 14 , wherein R 3 is hydroxy or an unsubstituted (C 1 to C 10 ) alkoxy.

19. The compound of claim 15 , wherein R 3 is an unsubstituted (C 1 to C 6 )alkyl.

20. The compound of claim 14 , wherein R 3 is an unsubstituted mono-cyclic (C 3 to C 6 ) cycloalkyl.

21. The compound of claim 14 , wherein R 3 is NH 2 or an unsubstituted —NC(═O)—C 1-6 alkyl.

22. The compound of claim 14 , wherein R 3 is —(C═O)OR 6 , wherein R 6 is an unsubstituted (C 1 to C 30 ) alkyl; or —O(C═O)R 5 , wherein R 5 is a substituted benzyl or

23. A pharmaceutical composition comprising an effective amount of a compound of claim 14 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

24. The compound of claim 16 , wherein R 3 is an unsubstituted (C 2 to C 6 )alkyl.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2025
From: RECURIUM IP HOLDINGS, LLC
To: KTHERA, LLC
Reel/Frame 070653/0373 →
CHANGE OF NAME Recorded Jan 3, 2020
From: ZENO ROYALTIES & MILESTONES, LLC
To: RECURIUM IP HOLDINGS, LLC
Reel/Frame 051478/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2018
From: KALYRA PHARMACEUTICALS, INC.
To: ZENO ROYALTIES & MILESTONES, LLC
Reel/Frame 047693/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2018
From: KALYRA PHARMACEUTICALS, INC.
To: ZENO ROYALTIES & MILESTONES, LLC
Reel/Frame 047422/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2018
From: BUNKER, KEVIN DUANE
To: KALYRA PHARMACEUTICALS, INC.
Reel/Frame 044880/0873 →
Continuity (4)
Continuation 15262852 · Sep 12, 2016
Continuation 14439636
Provisional Application 61781580 · Mar 14, 2013
Related Publication 20180042871A1 · Feb 15, 2018